- Conditions
- COPD
- Interventions
- Inhaled PT005, Inhaled Placebo, Formoterol Fumarate 12 µg (Foradil Aerolizer)
- Drug
- Lead sponsor
- Pearl Therapeutics, Inc.
- Industry
- Eligibility
- 40 Years to 80 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Spartanburg, South Carolina
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 937–960
of 3,754
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Diabetic Peripheral Neuropathic Pain
- Interventions
- V3381, Placebo
- Drug
- Lead sponsor
- Vernalis (R&D) Ltd
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 161 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 9
- States / cities
- Little Rock, Arkansas • Ocala, Florida • St. Petersburg, Florida + 5 more
- Conditions
- Irritable Bowel Syndrome
- Interventions
- Stress Management and Resilience Training Program, Self-Management Stress Reduction Program
- Behavioral
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Reduction in Hypertrophic Skin Scarring
- Interventions
- EXC 001
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 12
- States / cities
- Pasadena, California • Whittier, California • Lake Worth, Florida + 7 more
- Conditions
- Pancreatic Cancer
- Interventions
- protein analysis, laboratory biomarker analysis
- Genetic · Other
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 3
- States / cities
- Nashville, Tennessee
- Conditions
- Crigler-Najjar Syndrome
- Interventions
- AT342
- Genetic
- Lead sponsor
- Audentes Therapeutics
- Industry
- Eligibility
- 1 Year and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 2
- States / cities
- The Bronx, New York • Strasburg, Pennsylvania
- Conditions
- Multiple Sclerosis
- Interventions
- ONO-4641
- Drug
- Lead sponsor
- EMD Serono
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 340 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 20
- States / cities
- Tucson, Arizona • Aurora, Colorado • Fort Collins, Colorado + 17 more
- Conditions
- Breast Neoplasm, Colon Neoplasm, Pancreatic Neoplasm, Bladder Neoplasm
- Interventions
- MLN8054
- Drug
- Lead sponsor
- Millennium Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2005
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Breast Cancer
- Interventions
- Trastuzumab
- Radiation
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2019
- U.S. locations
- 8
- States / cities
- San Francisco, California • Chicago, Illinois • Boston, Massachusetts + 3 more
- Conditions
- Stage III Fallopian Tube Cancer, Stage III Ovarian Cancer, Stage III Primary Peritoneal Cancer, Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Cancer, Stage IIIA Primary Peritoneal Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIB Ovarian Cancer, Stage IIIB Primary Peritoneal Cancer, Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Primary Peritoneal Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Cancer, Stage IV Primary Peritoneal Cancer
- Interventions
- Carboplatin, Gynecological Surgical Procedure, Laboratory Biomarker Analysis, Paclitaxel, pUMVC3-hIGFBP-2 Multi-Epitope Plasmid DNA Vaccine
- Drug · Procedure · Other + 1 more
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Thrombotic Thrombocytopenic Purpura
- Interventions
- Danazol
- Drug
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2015
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Restrictive Scar Contracture, Restrictive Hypertrophic Scar, Burn Scar Contractures, Burn Scar
- Interventions
- ICX-RHY-013
- Drug
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia With BCR-ABL1, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia
- Interventions
- Blinatumomab, Cyclophosphamide, Cytarabine, Filgrastim, Methotrexate, Pegfilgrastim, Ponatinib, Rituximab, Vincristine
- Biological · Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- HIV Infections
- Interventions
- Health Access Coalitions, Social Media, Peer Support, Promoting Human Autonomy Support & Empathy (PHASE)
- Behavioral
- Lead sponsor
- HIV Prevention Trials Network
- Network
- Eligibility
- 15 Years and older · Male only
- Enrollment
- 2,700 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Cancer
- Interventions
- ALB 109564(a) (12´-methylthiovinblastine dihydrochloride)
- Drug
- Lead sponsor
- Albany Molecular Research, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • The Bronx, New York
- Conditions
- Pain
- Interventions
- VX-548, Moxifloxacin, Moxifloxacin Placebo, VX-548 Placebo
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023
- U.S. locations
- 2
- States / cities
- Lenexa, Kansas • Salt Lake City, Utah
- Conditions
- Colon Cancer, Peripheral Neuropathy
- Interventions
- Cryotherapy Gloves
- Device
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 2
- States / cities
- Mineola, New York • New York, New York
- Conditions
- AML/MDS, Acute Myeloid Leukemia, Myelodysplastic Syndromes
- Interventions
- Danvatirsen, Danvatirsen + Venetoclax
- Drug · Combination Product
- Lead sponsor
- Montefiore Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2030
- U.S. locations
- 2
- States / cities
- The Bronx, New York • Houston, Texas
- Conditions
- Neurotoxicity
- Interventions
- Vitamin D3
- Drug
- Lead sponsor
- Gerald Higa, PharmD.
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- Morgantown, West Virginia
- Conditions
- Pancreas Cancer, Pancreas Cyst, Pancreatic Ductal Adenocarcinoma, Genetic Predisposition
- Interventions
- Not listed
- Lead sponsor
- Arbor Research Collaborative for Health
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 20,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2030
- U.S. locations
- 46
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Burbank, California + 39 more
- Conditions
- Chronic Graft Versus Host Disease
- Interventions
- Belumosudil
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 1 Year to 18 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 7
- States / cities
- Los Angeles, California • Washington D.C., District of Columbia • Atlanta, Georgia + 4 more
- Conditions
- Executive Function
- Interventions
- Theta-frequency near-zero phase lag stimulation, Theta-frequency anti-synchrony stimulation, Arrhythmic near-zero phase lag stimulation, Arrhythmic independent stimulation, Alpha-frequency near-zero phase lag stimulation, Alpha-frequency anti-synchrony stimulation
- Device
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 71 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Relapsed/Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Richter's Syndrome, Treatment-naïve High Risk Chronic Lymphocytic Leukemia
- Interventions
- Epcoritamab, rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone, Venetoclax, Lenalidomide, Pirtobrutinib
- Biological · Drug
- Lead sponsor
- Genmab
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 194 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2028
- U.S. locations
- 23
- States / cities
- Birmingham, Alabama • California City, California • Duarte, California + 18 more
- Conditions
- Solid Tumor, Breast Cancer, Colon Cancer, Cholangiocarcinoma, Soft Tissue Sarcoma
- Interventions
- LY3039478, Taladegib, Abemaciclib, Cisplatin, Gemcitabine, Carboplatin, LY3023414
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 94 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 4
- States / cities
- Miami, Florida • Detroit, Michigan • New York, New York + 1 more